Literature DB >> 25487495

Clinical features of ATRX or DAXX mutated neuroblastoma.

Sho Kurihara1, Eiso Hiyama2, Yoshiyuki Onitake1, Emi Yamaoka3, Keiko Hiyama3.   

Abstract

PURPOSE: Previously, we reported that alternative lengthening of telomere (ALT) may be a biomarker for chemo-sensitivity and late recurrence in neuroblastoma (NBL). In this study, alterations of ATRX or DAXX, which both encode chromatin remodeling proteins in telomeric region, and their relationship to ALT were examined in NBLs.
METHODS: Our previous report on 121 NBLs revealed 11 NBLs with elongated telomeres by ALT. In these NBLs, ATRX or DAXX gene alterations were identified using next-generation sequencing and compared to clinical and other biological factors.
RESULTS: In 11 ALT cases, DAXX mutations were detected in one case, and ATRX alterations were detected in 10 cases. Except for one case, no DAXX or ATRX alterations were detected in 110 tumors with normal or shortened telomeres. MYCN amplification was not detected in ATRX altered tumors. In ALT cases, three infants showed ATRX deletions, and all seven cases detected after 18months of age showed poor prognosis.
CONCLUSIONS: In NBLs, ALT was caused by ATRX or DAXX alterations. ATRX altered cases without MYCN amplification detected at greater than 18months showed poor prognosis, suggesting that ATRX or DAXX alterations are a particular NBL subtype. Since these tumors showed chemo-resistance and late recurrence, complete resection in a surgical approach should be performed to improve patient prognosis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALT; ATRX; DAXX; Mutation; Neuroblastoma; Prognosis; Telomere

Mesh:

Substances:

Year:  2014        PMID: 25487495     DOI: 10.1016/j.jpedsurg.2014.09.029

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  14 in total

Review 1.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

2.  ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.

Authors:  Balakrishna Koneru; Ahsan Farooqi; Thinh H Nguyen; Wan Hsi Chen; Ashly Hindle; Cody Eslinger; Monish Ram Makena; Trevor A Burrow; Joanne Wilson; Aaron Smith; Venkatesh Pilla Reddy; Elaine Cadogan; Stephen T Durant; C Patrick Reynolds
Journal:  Sci Transl Med       Date:  2021-08-18       Impact factor: 19.319

3.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 4.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Authors:  Kristopher R Bosse; John M Maris
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

5.  Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma.

Authors:  Xao X Tang; Hiroyuki Shimada; Naohiko Ikegaki
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

6.  Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.

Authors:  Michael R van Gerven; Eva Bozsaky; Yvette A H Matser; Julian Vosseberg; Sabine Taschner-Mandl; Jan Koster; Godelieve A M Tytgat; Jan J Molenaar; Marlinde van den Boogaard
Journal:  Cancer Sci       Date:  2022-04-26       Impact factor: 6.518

7.  Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.

Authors:  Angela Bellini; Nadia Bessoltane-Bentahar; Jaydutt Bhalshankar; Nathalie Clement; Virginie Raynal; Sylvain Baulande; Virginie Bernard; Adrien Danzon; Mathieu Chicard; Léo Colmet-Daage; Gaelle Pierron; Laura Le Roux; Julien M Planchon; Valérie Combaret; Eve Lapouble; Nadège Corradini; Estelle Thebaud; Marion Gambart; Dominique Valteau-Couanet; Jean Michon; Caroline Louis-Brennetot; Isabelle Janoueix-Lerosey; Anne-Sophie Defachelles; Franck Bourdeaut; Olivier Delattre; Gudrun Schleiermacher
Journal:  Int J Cancer       Date:  2019-05-31       Impact factor: 7.396

8.  Enhanced UV Resistance Role of Death Domain-Associated Protein in Human MDA-MB-231 Breast Cancer Cells by Regulation of G2 DNA Damage Checkpoint.

Authors:  Zhiyan Shan; Li Liu; Jingling Shen; Haiyue Hao; Honghong Zhang; Lei Lei; Feng Liu; Zhipeng Wang
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 9.  Telomere Maintenance in Pediatric Cancer.

Authors:  Sandra Ackermann; Matthias Fischer
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

10.  Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.

Authors:  Samuel W Brady; Yanling Liu; Xiaotu Ma; Alexander M Gout; Kohei Hagiwara; Xin Zhou; Jian Wang; Michael Macias; Xiaolong Chen; John Easton; Heather L Mulder; Michael Rusch; Lu Wang; Joy Nakitandwe; Shaohua Lei; Eric M Davis; Arlene Naranjo; Cheng Cheng; John M Maris; James R Downing; Nai-Kong V Cheung; Michael D Hogarty; Michael A Dyer; Jinghui Zhang
Journal:  Nat Commun       Date:  2020-10-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.